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Abstract
CDKN3 (cyclin-dependent kinase inhibitor 3), a dual specificity protein phosphatase, dephosphorylates cyclin-dependent
kinases (CDKs) and thus functions as a key negative regulator of cell cycle progression. Deregulation or mutations of CDNK3
have been implicated in various cancers. However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia
(CML) remains unknown. Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis.
Overexpression of CDKN3 sensitized the K562 leukemic cells to imanitib-induced apoptosis and dramatically inhibited K562
xenografted tumor growth in nude mouse model. Ectopic expression of CDKN3 significantly reduced the efficiency of Bcr-
Abl-mediated transformation of FDCP1 cells to growth factor independence. In contrast, depletion of CDKN3 expression
conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia
in mice. In addition, we found that CDKN3 mutant (CDKN3-C140S) devoid of the phosphatase activity failed to affect the
K562 leukemic cell survival and xenografted tumor growth, suggesting that the phosphatase of CDKN3 was required for its
tumor suppressor function. Furthermore, we observed that overexpression of CDKN3 reduced the leukemic cell survival by
dephosphorylating CDK2, thereby inhibiting CDK2-dependent XIAP expression. Moreover, overexpression of CDKN3
delayed G1/S transition in K562 leukemic cells. Our results highlight the importance of CDKN3 in Bcr-Abl-mediated
leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.
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Introduction
Chronic myelogenous leukemia (CML) is a hematopoietic
malignancy characterized by the presence of the Philadelphia
chromosome that arises from a reciprocal translocation between
the Bcr gene on chromosome 22 and the c-Abl gene on
chromosome 9, resulting in the formation of Bcr-Abl oncogene
[1,2]. Previous studies have revealed that deregulation of multiple
signaling pathways associated with cell survival and proliferation,
including phosphoinositide-3-kinase (PI3K)/AKT, RAS, and
Janus kinase (JAK)/signal transducer and activator of transcription
(STAT), underlies Bcr-Abl-induced tumorigenesis [3–5]. Howev-
er, the precise mechanisms by which Bcr-Abl causes leukemogen-
esis are not fully clarified.
Dysregulation of cell cycle causes aberrant cell proliferation,
which potentiates genomic instability and cancer development [6–
8]. It is well known that Bcr-Abl expression in hematopoietic cells
promotes cell cycle progression from G1 to S phase, leading to
cytokine-independent proliferation [9,10]. Bcr-Abl may downreg-
ulate expression of cyclin-dependent kinase (CDK) inhibitor
p27Kip1 not only by suppressing its mRNA expression but also
by enhancing its protein degradation through the PI3K/AKT-
mediated proteasome pathway, resulting in activation of CDKs to
accelerate cell cycle progression [11–13]. Although alterations in
cell cycle progression and cell proliferation have been implicated
in Bcr-Abl-mediated tumorigenesis, the precise contribution of
relevant signaling molecules to the development of CML remains
to be further defined [9].
As a member of the dual specificity protein phosphatase family,
CDKN3 (CDK inhibitor 3, also called CDI1 or KAP) plays a key
role in regulating cell division [8,14–17]. The gene encoding
CDKN3 protein is located on chromosome 14q22 [18]. It is well
known that CDKN3 can specifically dephosphorylate and
inactivate CDK2, thereby inhibiting G1/S cell cycle progression
[19]. CDKN3 also interacts with CDK1 (also known as Cdc2 in
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fission yeast) and controls progression through mitosis by
dephosphorylating CDC2 at Thr161 and consequently reducing
phosphorylation of CKb at Ser209 [17]. CDKN3 has been
suggested to function as a tumor suppressor, and its loss of function
was found in a variety of cancers [17,20]. For example,
downregulation of CDKN3 has been found in glioblastoma [17].
Loss of CDKN3 has also been observed in hepatocellular
carcinoma [20]. Contradictorily, CDKN3 is highly expressed in
breast and prostate cancers, and blocking CDKN3 expression can
inhibit the transformation [21]. In addition, elevated levels of
CDKN3 occur in renal cell carcinoma (RCC), and enforced
CDKN3 expression significantly enhances cell proliferation and
xenograft tumor growth in renal cancer cells, suggesting an
oncogenic function of CDKN3 [22]. While more work is needed
to dissect the role of the CDKN3 in cancer, these findings suggest
that CDKN3 may potentially function either as an oncogene or a
tumor suppressor. Interestingly, several spliced transcript variants
encoding different isoforms of CDKN3 were found in diverse
cancers, implying that these isoforms may be associated with
specific tumor formation [23,24]. Despite the importance of
CDKN3 in tumorigenesis, how CDKN3 plays a role in Bcr-Abl-
induced leukemia and the mechanism by which CDKN3 functions
to impact Bcr-Abl-mediated cellular transformation are largely
unknown.
Here we found that CDKN3 acted as a tumor suppressor in
Bcr-Abl-induced tumorigenesis. Overexpression of CDKN3 de-
layed G1/S transition, sensitized imatinib-induced apoptosis in
K562 leukemic cells, and inhibited the growth of xenografted
leukemias in nude mice. In addition, we observed that forced
expression of CDKN3 significantly impaired the efficiency of Bcr-
Abl-mediated FDCP1 cellular transformation. Furthermore, we
revealed that CDKN3 reduced the cell survival by disrupting
CDK2-dependent expression of XIAP. Together, our experiments
establish an important role for CDKN3 in Bcr-Abl-mediated
leukemogenesis, and provide a potential new therapeutic target for
treatment of Abl-positive malignancies.
Materials and Methods
Cell lines and cell culture
Cell lines 293T and K562 were purchased from American Type
Culture Collection (ATCC) and grown in Dulbecco’s modified
Eagle medium (DMEM) or RPMI1640 supplemented with 10%
fetal bovine serum (FBS) and antibiotics (penicillin and strepto-
mycin) as previously described [4]. SUP-B15 cell line was obtained
from Cell Resource Center, Chinese Academy of Sciences in
Shanghai and cultured in IMEM supplemented with 20% FBS
and antibiotics. FDCP1 cell line was purchased from ATCC and
grown in RPMI1640 supplemented with 10% fetal bovine serum
containing antibiotics and 3 ng/ml murine IL3. CDKN3-overex-
pressing K562 cells were generated by infecting the cells with
retroviruses encoding FLAG-tagged CDKN3 using the pMSCV-
IRES-GFP vector as previously described [5]. Short hairpin RNA
(shRNA)-expressing K562 or SUP-B15 cells were generated by
infection of the cells with lentiviruses expressing specific shRNA in
pSIH-H1-GFP vector as described previously [5].
Antibodies and reagents
The following antibodies were used in this study: anti-FLAG
(Sigma, Saint Louis, MO, USA); anti-CDK2 and anti-phospho-
CDK2 Thr160 (Santa Cruz Biotechnology, Dallas, TX, USA);
anti-c-Abl (Merck Millipore, Billerica, MA, USA); anti-XIAP (Cell
Signaling, Danvers, MA, USA). All other antibodies were obtained
as described previously [25]. Thymidine and nocodazole were
purchased from Sigma, RNase Inhibitor was obtained from
Thermo Scientific (Waltham, MA, USA), and murine IL3 was
purchased from PEPRO TECH (Rocky Hill, NJ, USA).
Construction of CDKN3 expressing and specific shRNA
expressing vectors
FLAG-tagged CDKN3 was subcloned into pMSCV-IRES-GFP
to generate pMSCV-CDKN3-IRES-GFP. CDKN3 mutant
(CDKN3-C140S) devoid of the phosphatase activity and CDK2
dominant-negative mutant (CDK2-D145N) were generated using
a QuickChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA). The shRNA-expressing constructs were generated by
subcloning shRNA oligonucleotides into BamH I and EcoR I sites
of pSIH-H1-GFP vector (System Biosciences, Mountain View,
CA, USA) as previously described [26]. The shRNA sequence
targeting CDKN3 is 59-GCCGCCCAGTTCAATACAAAC-39.
Reverse transcription PCR (RT-PCR) and real-time PCR
Total RNA was extracted using TRizol reagent (Invitrogen,
Carlsbad, CA, USA). cDNA was synthesized using GoScriptTM
Reverse Transcription System (Promega, Madison, WI, USA) and
oligo (dT) primers (Takara, Dalian, China) by following the
manufacturer’s instruction. Briefly, 4 mg RNA was mixed with
0.5 mg oligo (dT) primers and nuclease-free water to a final volume
of 5 ml. This mixture was heated at 70uC for 5 minutes and then
immediately chilled on ice for 5 minutes, followed by addition of
15 ml GoScriptTM reverse transcription mix (1.5 mM MgCl2,
0.5 mM each dNTP, 20 units of RiboLock RNase Inhibitor, 160
units of GoScript Reverse Transcriptase). The reaction was then
performed by annealing at 25uC for 5 minutes, extending at 42uC
for 60 minutes and inactivating reverse transcriptase at 70uC for
15 minutes. The synthesized cDNA was amplified by PCR using
rTaq DNA polymerase (Takara, Tokyo, Japan) with specific
primers following the manufacturer’s instruction. The quantitative
real-time PCR was conducted with SuperReal PreMix Plus kit
(TIANGEN, Beijing, China) following the manufacturer’s instruc-
tion. The following primers were used for both PCR and real-time
PCR: human CDKN3 forward, (59-GGACTCCTGACATAGC-
CAGC-39) and reverse (59-CTGTATTGCCCCGGATCCTC-
39); human XIAP forward, (59-TGAAAATAGTGCCACG-
CAGTCT-39) and reverse (59-CTGGCCAGTTCTGAAAG-
GACTT-39). Expression level of b-actin or GAPDH was used as
a control.
Western blotting
Western blotting was conducted as previously described [27,28].
Briefly, cells were treated as indicated in the figure legends,
harvested, and lysed for protein collection. Samples were then
separated on SDS-polyacrylamide gel, transferred to a nitrocellu-
lose membrane, and probed with antibodies as indicated.
Apoptosis and cell viability assay
Cell apoptosis assay was performed using KeyGEN Annexin V-
APC/propidium iodide (PI) Apoptosis Detection kit (KeyGEN
BioTECH, Nanjing, China) according to the manufacturer’s
instructions. Briefly, cells were treated with 5 mM or 10 mM
imatinib for the indicated times. The samples were washed with
ice cold phosphate-buffered saline (PBS) and stained with 2.5 mg/
ml Annexin V-APC and 1 mg/ml propidium iodide. The samples
were then examined by fluorescence-activated cell sorter (BD
Bioscience, San Jose, CA, USA) as previously described [5,29]. For
cell viability assay, cells were treated with 10 mM imatinib for
indicated time, washed with ice cold PBS, stained with 1 mg/ml of
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propidium iodide, and examined by fluorescence-activated cell
sorter as described previously [5,29]. All the data were analyzed by
FCS Express V3 Software (De Novo Software, Thornhill, Ontario,
Canada).
Bcr-Abl-mediated FDCP1 transformation
FDCP1 cells were infected with retroviruses carrying Bcr-Abl
oncogene by spin infection with 8 mg polybrene at 32uC for
2 hours. The infected cells were suspended in RPMI1640
containing 10% FBS and seeded in 96-well plates (each plate
was seeded with 46106 cells equally). The transformation
efficiency was scored by counting the number of wells that
displayed cytokine-independent growth 2 weeks after infection as
described previously [27].
Cell cycle synchronization and cell cycle analysis
K562 cells were synchronized at the G1/S transition as
previously described [30,31]. In brief, cells were treated with
2 mM of thymidine for 13.5 h and then released for 9 h, followed
by treatment with thymidine for 13.5 h. Cells were released for
2.5 h and subjected to flow cytometry analysis. To obtain cells in
mitosis, cells were treated with thymidine for 13.5 h and then
released for 6 h, followed by treatment with 100 ng/ml of
nocodazole for 6 h. Cells were released for 2 or 4 h, and subjected
to flow cytometry analysis. Cell cycle analysis was performed as
previously described [30,31]. Briefly, cells were collected at the
indicated time, fixed in 75% ethanol at 220uC overnight, then
washed and incubated with propidium iodide (5 mg/ml with 0.1%
RNase A) for 30 min. The samples were analyzed with a
fluorescence-activated cell sorter (BD Bioscience).
Nude mouse xenograft experiments
Female nude mice (5–6 weeks old) were obtained from Vital
River Laboratories (VRL) (Beijing, China). Nude-mouse injection
was performed as previously described [4]. Tumor growth was
monitored and measured in volume (length6height6width) at the
indicated time points. Bioluminescent imaging was performed to
detect tumors originating from the GFP-expressing cells. Mice
were anesthetized using 2% isoflurane and imaged using a cooled
CCD camera. Images were quantified as photons/s using the
indigo software (Berthold Technologies, Bad Wildbad, Germany).
Ethics statement
The mouse experimental design and protocols used in this study
were approved by ‘‘the regulation of the Institute of Microbiology,
Chinese Academy of Sciences of Research Ethics Committee’’
(Permit Number: PZIMCAS2013008). All mouse experimental
procedures were performed in accordance with the Regulations
for the Administration of Affairs Concerning Experimental
Animals approved by the State Council of People’s Republic of
China.
Statistical analysis
Results were expressed as mean values 6 standard error (mean
6 SE). Statistical significance was determined by Student’s t-test.
A level of P,0.05 was considered to be significant.
Results
CDKN3 negatively regulates K562 leukemic cell survival
in the presence of imatinib
Deregulation or mutation of CDKN3 has been associated with
a variety of human cancers [17,20,22,23,32], but it is unknown
whether it plays a role in Bcr-Abl-induced tumorigenesis. To
address this issue, we generated K562 leukemic cells stably
expressing wild type CDKN3 (CDKN3-WT), or empty vector
control (EV) (Figure 1A, Figure S1). These cells were treated with
10 mM of imatinib for up to 36 h, followed by Annexin V and PI
staining and flow cytometry analysis. We found that under these
culture conditions, approximately 50% of the control cells
remained viable after incubation with imatinib for 36 h. In
contrast, only approximately 31% of CDKN3-WT overexpressing
cells were viable under the same imatinib treatment (Figure 1B),
although overexpression of CDKN3 had no significant effect on
the cell survival in the absence of imatinib (Figure S2A). To rule
out the possibility of off-target responses caused by the imatinib
dose at 10 mM, we also treated K562 cells with 5 mM imatinib for
36 h. Similarly, overexpression of CDKN3 significantly reduced
the cell viability under this condition as compared with the control
(Figure S2B). Importantly, there was no significant difference in
cell survival between the control cells and cells expressing CDKN3
mutant (CDKN3-C140S) devoid of the phosphatase activity, in
response to imatinib treatment (Figures 1C and 1D). These data
suggest that CDKN3 overexpression promotes imatinib-induced
apoptosis in K562 cells, and that the phosphatase activity of
CDKN3 is required for its function in regulating leukemic cell
survival in the presence of imatinib.
To further confirm the role of CDKN3 in regulating the
survival of Bcr-Abl-transformed leukemic cells, K562 cell lines
stably expressing shRNA targeting CDKN3 (sh-CDKN3) or
luciferase (sh-luc) control were generated. Examination by
Western blotting, RT-PCR and real time PCR showed that
expression of CDKN3 was strongly diminished in cells expressing
related shRNA (Figure 1E, and Figure S1). However, depletion of
CDKN3 had no significant effect on the apoptosis of K562 cells
without imatinib treatment (Figure S2C). These cells were then
treated with 10 mM imatinib for indicated times and analyzed for
cell survival. As expected, our results showed that approximately
49% of the control cells remained viable after treatment with
imatinib for 36 h, while approximately 66% of the CDKN3
knockdown cells were viable under the same condition (Figure 1F),
indicating a critical role for CDKN3 in imatinib-induced apoptosis
of K562 leukemic cells. In addition, we also treated these K562
cells with 5 mM imatinib for 36 h. CDKN3 knockdown resulted in
an increase in cell viability after imatinib treatment as compared to
the control (Figure S2D). To better clarify the function of CDKN3
in Bcr-Abl tumorigenesis, we employed another Bcr-Abl positive
cell line SUP-B15 that expresses comparable level of CDKN3 to
K562 (Figure S3A). SUP-B15 cells stably expressing shRNA
against CDKN3 or luciferase were generated (Figure S3B). The
cells were then treated with 5 mM imatinib for 24 h and stained
with Annexin V and PI. Similarly, depletion of CDKN3
significantly increased the cell viability after treatment with
imatinib (Figure S3C). Taken together, these data implicate
CDKN3 as a negative regulator of leukemic cell survival in the
presence of imatinib.
Altering CDKN3 expression has profound effects on
Bcr-Abl-dependent tumor growth in a nude mouse
xenograft model
To understand whether CDKN3 regulates Bcr-Abl-mediated
tumorigenesis in vivo, nude mice were subcutaneously injected
with K562 cells stably expressing CDKN3-WT or empty vector as
control. Tumor volumes were measured each week after
inoculation. Remarkably, we observed that the tumors formed
by K562 cells overexpressing the CDKN3 phosphatase grew
clearly slower than those formed by control cells (Figure 2A and
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2B). Statistical analysis revealed that the tumor growth was
significantly inhibited by exogenous expression of CDKN3-WT in
K562 cells (Figures 2C). This finding was validated via biolumi-
nescent imaging analysis (Figure 2D) and confirmed in three
independent experiments. Additionally, Western blotting analysis
demonstrated the overexpression of CDKN3 in the slow growth
tumors (Figure 2E). In contrast, no significant difference was
observed in the growth of tumors formed by K562 cells
overexpressing phosphatase-dead CDKN3-C140S and control
cells (Figures 2F and 2G). Together, these findings revealed that
ectopic expression of wild type CDKN3, but not the phosphatase-
deficient CDKN3-C140S mutant, significantly impeded the
growth of the Bcr-Abl-driven K562 cells in the nude mouse
xenograft model.
Since overexpression of CDKN3 inhibited the growth of
leukemia in vivo, we hypothesized that decreased CDKN3
expression may promote the growth of leukemic tumors. To
address this possibility, nude mice were injected subcutaneously
with K562 cells stably expressing shRNA against CDKN3 (sh-
CDKN3) or luciferase (sh-luc) control. As hypothesized, we found
that silencing CDKN3 expression greatly promoted K562
xenografted tumor growth in nude mice (Figure 3A and 3B).
Statistical analysis showed that a significant enhancement of tumor
growth was induced by the knockdown of CDKN3 in K562 cells
(Figures 3C). These results further indicate that CDKN3 phos-
phatase acts as a tumor suppressor in Bcr-Abl-mediated tumor-
igenesis.
Figure 1. CDKN3 negatively regulates K562 cell survival. (A) Expression of CDKN3 in K562 cells stably overexpressing FLAG-tagged wild type
CDKN3 (CDKN3-WT) or empty vector (EV) was detected by Western blotting using indicated antibodies. (B) K562 cells stably overexpressing CDKN3-
WT or EV were treated with 10 mM of imatinib for the indicated time. Samples were stained with Annexin V-APC and PI, examined by flow cytometry
and analyzed by FCS Express V3. Plotted are results from three independent experiments. Error bars represent SEM, n=3; *P,0.05. (C) Shown is an
immunoblot examining FLAG-tagged CDKN3-C140S in K562 cells ectopically expressing CDKN3 mutant (CDKN3-C140S) or empty vector (EV). (D) Cell
viability of K562 cells expressing CDKN3-C140S or EV was assessed by flow cytometry after treatment with 10 mM of imatinib for 36 h. Samples were
stained with Annexin V-APC and PI. Plotted are results from three independent experiments. Error bars represent SEM, n= 3. (E) Shown is an
immunoblot examining shRNA-based knockdown of CDKN3. (F) K562 cells stably expressing sh-luc or sh-CDKN3 were treated with 10 mM imatinib for
the indicated time. Samples were then stained with Annexin V-APC and PI, followed by flow cytometry analysis. Plotted are results from three
independent experiments. Error bars represent SEM, n= 3; *P,0.05.
doi:10.1371/journal.pone.0111611.g001
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Forced expression of CDKN3 significantly reduced the
efficiency of Bcr-Abl-mediated transformation of FDCP1
cells to growth factor independence
To better define the role of CDKN3 in Bcr-Abl-mediated
cellular transformation, we generated bicistronic retroviruses
encoding Bcr-Abl and either GFP or CDKN3 (Figure 4A and
4B). Equal titer of these viruses was used to infect FDCP1 cells.
Efficiency of the viruses to transform FDCP1 cells to growth factor
independence was then assessed by counting the number of wells
containing Bcr-Abl-transformed cell clones. FDCP1 cells infected
with viruses carrying Bcr-Abl-IRES-GFP showed an average result
of 23 wells/96-well plate which displayed IL-3-independent
growth of cell clones. Interestingly, the exogenous expression of
CDKN3 remarkably impaired the transformation efficiency of
Bcr-Abl to 12 wells/96-well plate (Figure 4C). These data
Figure 2. Overexpression of CDKN3 dramatically inhibits K562 xenografted tumor growth in nude mice. (A) Nude mice were
subcutaneously injected with K562 cells stably expressing CDKN3-WT or EV. The tumor volumes were measured at indicated time points. Plotted are
results from three independent experiments. Error bars, SEM; n=9; *P,0.05. (B) Tumors were excised from mice. Shown are representative images
from four independent experiments with similar results. (C) Relative volume of tumors excised from nude mice injected with K562 cells expressing
CDKN3-WT or EV (control). The average volume of control tumors is set to 100%. Error bars, SEM; n= 9; *P,0.05. (D) Over a 21-day period after
inoculation, tumors formed by control or CDKN3-WT overexpressing K562 cells were measured by bioluminescent imaging. Shown are representative
images from at least three independent experiments with similar results. (E) CDKN3 expression in representative tumors expressing CDKN3-WT or EV
was examined by Western blotting. (F) Nude mice were subcutaneously injected with K562 cells stably expressing CDKN3-C140S or EV. The tumor
volumes were measured at indicated time points. Shown are volumes of tumors excised from nude mice injected with K562 cells expressing CDKN3-
C140S or EV. Plotted are results from three independent experiments. Error bars, SEM; n=9. (G) Tumors from nude mice injected with K562 cells
expressing CDKN3-C140S or EV were excised from mice. Shown are representative images from three independent experiments with similar results.
doi:10.1371/journal.pone.0111611.g002
Role of CDKN3 in Chronic Myelogenous Leukemia
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e111611
provided strong evidence that CDKN3 significantly inhibited Bcr-
Abl-induced cellular transformation and might function as a key
suppressor in Bcr-Abl-mediated tumorigenesis.
CDKN3 negatively regulates leukemia cells survival by
disrupting CDK2-dependent XIAP expression
Our experiments presented above demonstrated that the
phosphatase activity of CDKN3 is essential for its pro-apoptotic
activity in the CML leukemia cells. Previous studies have revealed
that CDKN3 could dephosphorylate cyclin-dependent kinase 2
(CDK2) and thus modulate cell proliferation [23,33]. It has been
shown that CDK2-dependent expression of anti-apoptotic protein
XIAP may account for the inefficient apoptosis in tumor cells
including Bcr-Abl expressing cells [34–36]. Thus, we hypothesized
that CDKN3 may inhibit the Bcr-Abl-mediated tumorigenesis at
least partially by dephosphorylating and inactivating CDK2 to
inhibit CDK2-dependent XIAP expression. To test this hypoth-
esis, we examined the activation of CDK2 and the expression of
XIAP in K562 cells expressing CDKN3-WT, CDKN3 specific
shRNA, empty vector control, or luciferase specific shRNA
control. The results showed that forced expression of CDKN3-
WT reduced the levels of CDK2 phosphorylation at Thr160.
Importantly, we observed that overexpression of CDKN3-WT
caused a marked decrease in mRNA and protein expression of
XIAP (Figure 5A and 5C). Conversely, depletion of CDKN3
increased CDK2 phosphorylation at Thr160 and the expression of
XIAP (Figure 5B and 5D). These data suggest that CDKN3 might
modulate leukemic cell survival at least partially through
regulating CDK2-dependent expression of the anti-apoptotic
regulator, XIAP.
To confirm the above findings, we generated CDKN3-
knockdown K562 cells stably expressing either CDK2-WT,
CDK2-D145N (dominant-negative mutant), or the control
(Figures 6A and 6B). These cells were subjected to imatinib
treatment and analyzed for cell survival. As shown in Figure 6C,
without imatinib treatment, depletion of CDKN3, overexpression
of CDK2-WT or CDK2-D145N did not significantly affect cell
viability in K562 cells as compared to the control cells. However,
consistently with our aforementioned findings, depletion of
CDKN3 significantly increased the survival of imatinib-treated
leukemic cells (Figure 6C). Overexpression of functional CDK2
further increased the survival of CDKN3-depleted leukemic cells
after treatment with imatinib, whereas ectopic expression of the
catalytically inactive CDK2-D145N mutant had the opposite
effect on survival of the CDKN3-deficient leukemic cells exposed
to imatinib. Together, these results reveal that activity of CDK2
regulated by CDKN3 is involved in imatinib-induced apoptosis in
K562 leukemic cells.
Overexpression of CDKN3 delays the G1/S transition in
K562 leukemic cells
Given that CDKN3 is a critical inhibitor for CDK2 [14,19], we
next evaluated the effect of CDKN3 on cell cycle progression in
K562 cells. K562 cells stably expressing CDKN3-WT or control
cells were synchronized at the G1/S boundary by thymidine
treatment, and then subjected to cell cycle analysis (Figure S4A).
As shown in Figure 7A, 61.65% of control cells resided in S phase,
whereas only 49.35% of CDKN3-WT overexpressing cells were in
S phase. This finding demonstrates that overexpression of
CDKN3 delays the G1/S transition in K562 leukemic cells.
Because CDKN3 also interacts with CDK1 [17], we further
examined whether overexpression of CDKN3 affects the timing of
mitotic exit upon nocodazole release in K562 cells (Figure S4B).
As shown in Figure 7B, 18.7% of the control cells were labeled as
G2/M phase population at 4 hours after release. Similarly, 17.1%
of CDKN3 overexpressing cells were in G2/M phase at this time
point, indicating that overexpression of CDKN3 had no significant
effect on the timing of the G2/M/G1 progression upon release
from nocodazole-induced mitotic spindle checkpoint arrest.
Together, these data reveal that enforced expression of CDKN3
delays the G1/S transition but has little effect on G2/M/G1
progression in Bcr-Abl positive K562 cells.
Figure 3. CDKN3 deficiency promotes K562 xenografted tumor
growth in nude mice. (A) Nude mice were subcutaneously injected
with K562 cells stably expressing sh-CDKN3 or sh-luc (control). The
tumor volumes were measured at indicated time points. Plotted are
results from three independent experiments. Error bars, SEM; n= 9; *P,
0.05. (B) Tumors were excised from mice. Shown are representative
images from four independent experiments with similar results. (C)
Relative volume of tumors excised from nude mice injected with K562
cells expressing sh-luc (control) or sh-CDKN3. The average volume of
control tumors is set to 100%. Error bars, SEM; n= 9; *P,0.05.
doi:10.1371/journal.pone.0111611.g003
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Discussion
Abnormal expression of CDKN3 is associated with a broad
spectrum of human cancers. Dual roles of CDKN3 acting either as
an oncogene or a tumor suppressor have been documented in
different tumors [17,20,21,23]. However, the functional relevance
of CDKN3 in Bcr-Abl-mediated leukemias remains elusive. Here,
for the first time, we present evidence that CDKN3 plays a crucial
role in Bcr-Abl-mediated tumorigenesis. Overexpression of
CDKN3 markedly sensitized K562 leukemic cells to imatinib-
induced apoptosis, and inhibited Bcr-Abl-dependent tumor
growth in nude mice. On the contrary, silencing CDKN3 greatly
rendered K562 cells resistant to imatinib-induced apoptosis, and
promoted K562 xenografted tumor growth in nude mice. In
addition, overexpression of CDKN3 remarkably inhibited the
transformation efficiency of FDCP1 cells induced by Bcr-Abl.
These results strongly indicate that CDKN3 acts as a tumor
suppressor in Bcr-Abl-mediated tumorigenesis.
Figure 4. Overexpression of CDKN3 significantly reduces the efficiency of Bcr-Abl-mediated FDCP1 cell transformation. (A) Shown
are constructs of bicistronic retroviruses carrying Bcr-Abl and GFP, Bcr-Abl and CDKN3-Flag, or empty vector (EV). (B) 293T cells were transfected with
the plasmids described in (A). Cells were harvested after 36 hours and protein expression was detected by Western blotting using indicated
antibodies. (C) FDCP1 cells were infected with retroviruses carrying empty vector, Bcr-Abl and GFP, or Bcr-Abl and CDKN3-Flag, and plated on 96-well
plates. Transformation efficiency was assessed as described in Materials and Methods. Plotted are the results from three independent experiments.
Error bars, SEM; n=3; *P,0.05.
doi:10.1371/journal.pone.0111611.g004
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Numerous studies have demonstrated that tumorgenesis in-
duced by the oncogenic Bcr-Abl kinase is associated with
dysregulation of a variety of signaling pathways, which endows
leukemic cells with malignant proliferation and defected apoptosis
[9,37,38]. It is well known that CDKN3 is a key inhibitor of
CDK2 [15]. CDK2 controls multiple cell cycle checkpoints,
including the G1/S transition and mitotic entry [39–41].
Activation of CDK2 requires the binding of cyclin E/A, but also
requires phosphorylation of CDK2 at Thr160 by CDK-activating
kinase (CAK) [39–41]. CDKN3 can form a stable complex with
CDK2, dephosphorylating Thr160 and thus inactivating CDK2
[42]. Our experiments demonstrated that overexpression of
CDKN3 was sufficient to prevent K562 leukemic cells from
entering S phase of the cell cycle, suggesting that CDKN3 may
negatively regulate proliferation of the leukemic cells by inacti-
vating CDK2 and thereby delaying the S-phase entry. This finding
is consistent with previously published observations in other
experimental systems, implicating CDKN3 as a S-phase gate-
keeper in multiple cell types [14–15,19].
In this study, we also investigated the mechanisms by which
CDKN3 promotes death of Bcr-Abl-driven leukemic cells upon
imatinib exposure. Our data showed that overexpression of wild
type CDKN3 significantly enhanced imatinib-induced apoptosis in
K562 cells. We found that ectopic expression of the phosphatase-
dead C140S CDKN3 mutant did not promote apoptosis under the
same conditions. In addition, enforced expression of the CDK2
dominant-negative mutant (CDK2-D145N) attenuated survival of
the CDKN3-knockdown leukemic cells, suggesting that increased
CDK2 activity is essential for increased survival of the CDKN3-
knockdown leukemic cells.
Several studies have revealed that XIAP, an anti-apoptotic
protein regulated by CDK2, plays an important role in controlling
cell survival [35,36,43,44]. Our results demonstrated that the
expression level of XIAP strongly correlated with the phosphor-
ylation status of CDK2 and the expression of CDKN3 in the K562
Figure 5. CDKN3 negatively regulates phosphorylation of CDK2 and expression of XIAP. (A) The levels of the indicated genes and
proteins were detected by RT-PCR and Western blotting, respectively, in K562 cells overexpressing CDKN3-WT or EV. (B) Experiments were performed
as described in (A). Shown are data from K562 cells expressing shRNA targeting CDKN3 or luciferase. (C) The mRNA expression of XIAP was detected
by real-time PCR in K562 cells expressing CDKN3-WT or EV. Plotted are the results from three independent experiments. Error bars, SEM; n=3; *P,
0.05. (D) Experiments were performed as described in (C). Plotted are the results from three independent experiments using K562 cells expressing
shRNA targeting CDKN3 or luciferase. Error bars, SEM; n= 3; *P,0.05.
doi:10.1371/journal.pone.0111611.g005
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leukemic cells, supporting the notion that CDKN3 may negatively
regulate leukemic cell survival by dephosphorylating CDK2,
leading to decreased expression of XIAP. Taken together, our
observations suggested that CDKN3 suppresses Bcr-Abl-induced
tumorigenesis likely through cell cycle arrest at the G1/S phases
and regulation of the apoptosis by altering the XIAP expression.
In summary, our results reveal that CDKN3 acts as a tumor
suppressor during Bcr-Abl-mediated tumorigenesis through con-
trol of both cell proliferation and cell survival. Downregulation or
Figure 6. CDK2 is involved in regulating CDKN3-mediated leukemic cell survival. (A) Shown is lentiviral vectors constructed in this study
that encode luciferase shRNA (sh-luc) control, CDKN3 shRNA (sh-CDKN3), sh-CDKN3 and either wild type CDK2 (CDK2-WT) or CDK2 dominant-
negative mutant (CDK2-D145N). (B) RT-PCR and Western blotting were performed to examine the expression of CDKN3, CDK2, and XIAP in K562 cells
expressing sh-CDKN3 alone, sh-CDKN3 and CDK2-WT, sh-CDKN3 and CDK2-D145N, or control. (C) Survival of K562 cells expressing sh-CDKN3, sh-
CDKN3 and CDK2-WT, sh-CDKN3 and CDK2-D145N, or the control was analyzed by flow cytometry after treatment with or without 10 mM of imatinib
for 48 h. Plotted are results from three independent experiments. Error bars represent SEM, n= 3; *P,0.05.
doi:10.1371/journal.pone.0111611.g006
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mutation of CDKN3 may increase cell proliferation and confer
high resistance to imatinib-induced apoptosis in Bcr-Abl-positive
leukemic cells. However, further studies are needed to address the
precise mechanisms by which CDKN3 impacts these processes. In
addition, future work will also explore the proposed role of
inactivation of the CDKN3 tumor suppressor pathway in human
leukemia. Whether this pathway has any prognostic or therapeutic
significance in the leukemia induced by Abl oncogenes also
remains to be determined.
Supporting Information
Figure S1 Generation of K562 cell lines stably express-
ing CDKN3, CDKN3 shRNA, or the controls. (A)
Generation of K562 cells stably overexpressing CDKN3-WT or
empty vector (EV). Retroviruses encoding CDKN3-WT or EV
were produced in 293T cells. Cell culture supernatants containing
retroviruses were collected and filtered through a 0.22-mm MCE
membrane (Millipore). K562 cells were infected with the
retroviruses and GFP-positive K562 cells were sorted by flow
cytometry. Shown are micrographs of these K562 cell lines
obtained from a fluorescent microscope (Axiovert 200M; Zeiss,
Oberkochen, Germany). (B) Experiments were performed as
described in (A). Shown are micrographs of K562 cell lines stably
expressing shRNA targeting CDKN3 or luciferase control
obtained from a fluorescent microscope (Axiovert 200M; Zeiss,
Oberkochen, Germany). (C) shRNA-based knockdown of
CDKN3 was examined by real-time PCR in K562 cells expressing
specific shRNAs. Plotted are results from three independent
experiments. Error bars, SEM; n=3; *P,0.05. (D) RT-PCR was
performed to examine CDKN3 mRNA levels in cells described in
(C).
(TIF)
Figure S2 CDKN3 promotes K562 cell apoptosis in-
duced by imatinib. (A) K562 cells stably overexpressing
CDKN3-WT or empty vector (EV) were stained with Annexin
V-APC and PI, examined by flow cytometry and analyzed by FCS
Express V3. Plotted are results from three independent experi-
ments. Error bars represent SEM, n=3. (B) K562 cells described
in (A) were treated with 5 mM imatinib for 36 h. Samples were
analyzed as described in (A). Plotted are results from three
independent experiments. Error bars, SEM; n=3; *P,0.05. (C)
Experiments were performed as described in (A). Plotted are the
results from three independent experiments using K562 cells
expressing shRNA against CDKN3 or luciferase. Error bars,
SEM; n=3. (D) K562 cells expressing shRNA against CDKN3 or
luciferase were treated with 5 mM imatinib for 36 h. Samples were
analyzed as described in (A). Plotted are results from three
independent experiments. Error bars represent SEM, n=3; *P,
0.05.
(TIF)
Figure S3 Disruption of CDKN3 expression increased
the survival of Bcr-Abl positive SUP-B15 cell. (A) The
mRNA expression of CDKN3 in K562 and SUP-B15 cells were
measured by RT-PCR. (B) shRNA-based knockdown of CDKN3
was examined in SUP-B15 cells expressing shRNA targeting
CDKN3 or luciferase by real-time PCR. Shown are results from
three independent experiments. Error bars, SEM; n=3; *P,0.05.
(C) SUP-B15 cells described in (B) were treated with 5 mM
imatinib for 24 h and stained with Annexin V-APC/PI. Samples
were analyzed by flow cytometry and FCS Express V3. Plotted are
results from three independent experiments. Error bars, SEM;
n=3; *P,0.05.
(TIF)
Figure S4 Schematic view of experimental design to
examine the impact of CDKN3 on cell cycle progression.
(A) K562 cells expressing CDKN3-WT or empty vector (EV) were
treated with thymidine (2 mM) for 13.5 h, released for 9 h and
then treated with thymidine (2 mM) for 13.5 h again. Cells were
released for 2.5 h and subjected to flow cytometry analysis. (B)
Cells described in (A) were treated by 2 mM of thymidine for
13.5 h, released for 6 h, and then treated by 100 ng/ml of
nocodazole for 6 h. Then cells were released for indicated time
and examined by flow cytometry.
(TIF)
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